The HIV-1 envelope protein gp120 impairs B cell proliferation by inducing TGF-β1 production and FcRL4 expression.
Katija Jelicic, Raffaello Cimbro, Fatima Nawaz...
https://pubmed.ncbi.nlm.nih.gov/24162774/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-08-07
2419
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are investigating the virologic and immunologic characteristics of HIV infection, along with other infectious and non-infectious immune deficiency diseases, to better understand how HIV causes disease. Due to the lack of effective animal models, the study uses human peripheral blood cells to examine HIV infection both inside the body and in laboratory settings. The goal is to explore various pathogenic aspects of HIV and immune system regulation using human immune cells. Participants include individuals living with or without HIV, other infectious diseases, or immunodeficiencies. The study collects blood products and other biological samples from these groups to support research by NIH Intramural Investigators. Samples are used throughout the study to investigate HIV and related immune conditions, including genomic and proteomic comparisons between affected individuals and healthy volunteers. During the study, participants provide blood samples and undergo assessments such as blood pressure, pulse, and blood counts. They also complete informed consent and agree to allow their samples to be used in future HIV research. Researchers measure virologic and immunologic markers of HIV and other immune deficiencies. The study is observational, with ongoing sample collection and analysis to better understand disease processes in adults aged 18 to 120 years.
CONDITIONS
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV
C
Catherine A Seamon, R.N.
S
Susan L Moir, Ph.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Medstar Health Research Institute
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Katija Jelicic, Raffaello Cimbro, Fatima Nawaz...
https://pubmed.ncbi.nlm.nih.gov/24162774/David J Auerbach, Yin Lin, Huiyi Miao...
https://pubmed.ncbi.nlm.nih.gov/22645343/Cecile Le Saout, Rebecca B Hasley, Hiromi Imamichi...
https://pubmed.ncbi.nlm.nih.gov/24603698/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
Medstar Health Research Institute
Collaborating Sponsor